Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Kadmon Holdings Llc (KDMN)

Kadmon Holdings Llc (KDMN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 390,201
  • Shares Outstanding, K 129,635
  • Annual Sales, $ 1,400 K
  • Annual Income, $ -54,250 K
  • 60-Month Beta 2.22
  • Price/Sales 264.66
  • Price/Cash Flow N/A
  • Price/Book 3.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.18
  • Number of Estimates 2
  • High Estimate -0.18
  • Low Estimate -0.18
  • Prior Year -0.13
  • Growth Rate Est. (year over year) -38.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.58 +15.89%
on 10/14/19
3.29 -9.12%
on 10/28/19
+0.39 (+15.00%)
since 10/11/19
3-Month
2.04 +46.57%
on 08/30/19
3.29 -9.12%
on 10/28/19
+0.58 (+24.07%)
since 08/09/19
52-Week
1.63 +83.44%
on 06/25/19
3.29 -9.12%
on 10/28/19
+0.35 (+13.26%)
since 11/09/18

Most Recent Stories

More News
Kadmon Announces that KD025 Met Primary Endpoint at Interim Analysis of Pivotal Trial in Chronic Graft-Versus-Host Disease

KD025 Achieved ORRs of 64% with KD025 200 mg QD and 67% with KD025 200 mg BID Conference Call Today at 5:00 p.m. Eastern Time

KDMN : 2.99 (-0.66%)
Kadmon Establishes Strategic Partnership with BioNova to Develop and Commercialize KD025 for the Treatment of GVHD in China

NEW YORK, NY / ACCESSWIRE / November 7, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced a strategic partnership with BioNova Pharmaceuticals Ltd. (BioNova) to form a joint venture to exclusively...

KDMN : 2.99 (-0.66%)
Kadmon Provides Business Update and Reports Third Quarter 2019 Financial Results

Kadmon Holdings, Inc. (NYSE:KDMN) today provided a business update and reported financial and operational results for the third quarter of 2019.

KDMN : 2.99 (-0.66%)
MGTX : 15.44 (+6.78%)
Kadmon Announces FDA Approval of CLOVIQUE (TM), A Room-Temperature Stable Trientine Hydrochloride Product

Product Offers Room Temperature Stability, Improving Convenience for Patients

KDMN : 2.99 (-0.66%)
Companies Turn to Advanced Therapies to Curb the Spread of Cancer

In 2019, the American Cancer Society projected 1.76 million new cancer cases diagnosed and the number of deaths to stand at 606,880 in the U.S. Overall, the alarming projection has caused concern within...

ONPH : 0.0302 (-2.58%)
KDMN : 2.99 (-0.66%)
ADXS : 0.33 (-1.51%)
SLS : 5.65 (-1.74%)
GERN : 1.48 (unch)
Kadmon Announces Sale of 1.4 Million Shares of MeiraGTx Holdings plc

NEW YORK, NY / ACCESSWIRE / October 3, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the Company has entered into a transaction to divest approximately 1.4 million shares of MeiraGTx Holdings...

KDMN : 2.99 (-0.66%)
Kadmon to Participate in Upcoming Investor Conferences

NEW YORK, NY / ACCESSWIRE / September 23, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will participate in the following...

KDMN : 2.99 (-0.66%)
Kadmon Announces FDA Approval of Generic Trientine Hydrochloride

NEW YORK, NY / ACCESSWIRE / September 17, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the U.S. Food and Drug Administration (FDA) has approved its generic Trientine Hydrochloride Capsules...

KDMN : 2.99 (-0.66%)
Kadmon to Participate in Upcoming Investor Conferences

NEW YORK, NY / ACCESSWIRE / September 3, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will participate in the following investor...

KDMN : 2.99 (-0.66%)
Kadmon Announces Appointment of Gregory S. Moss as Executive Vice President, General Counsel and Corporate Secretary

NEW YORK, NY / ACCESSWIRE / August 30, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced the appointment of Gregory S. Moss, Esq. as Executive Vice President, General Counsel and Corporate Secretary....

KDMN : 2.99 (-0.66%)
MGTX : 15.44 (+6.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade KDMN with:

Business Summary

Kadmon Holdings, Inc. is a biopharmaceutical company. It engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The company is developing product candidates within autoimmune and fibrotic diseases, oncology...

See More

Key Turning Points

2nd Resistance Point 3.24
1st Resistance Point 3.11
Last Price 2.99
1st Support Level 2.89
2nd Support Level 2.80

See More

52-Week High 3.29
Last Price 2.99
Fibonacci 61.8% 2.66
Fibonacci 50% 2.46
Fibonacci 38.2% 2.26
52-Week Low 1.63

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar